Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Breast Neoplasms 211Neoplasm Metastasis 16Neoplasms 9Breast Neoplasms, Male 7Breast Diseases 7Ovarian Neoplasms 4Endometrial Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Intraductal, Noninfiltrating 3Breast Carcinoma In Situ 3Breast Cancer Metastatic 3Advanced Breast Cancer 3Recurrence 2Prostatic Neoplasms 2Neoplasms by Site 2Carcinoma, Renal Cell 2Bulbo-Spinal Atrophy, X-Linked 2Uterine Cervical Neoplasms 1Unilateral Breast Neoplasms 1Tuberous Sclerosis 1Triple Negative Breast Neoplasms 1Thoracic Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sleep Wake Disorders 1Skin Diseases 1Sexuality 1Sexual Dysfunctions, Psychological 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Primary Breast Cancer ER+ve 1

Interventions

Gemcitabine 679130-nm albumin-bound paclitaxel 198Fluorouracil 186Oxaliplatin 175Albumin-Bound Paclitaxel 151Capecitabine 137Leucovorin 131Irinotecan 113Radiotherapy 95Taxes 83pembrolizumab 80Cisplatin 72Erlotinib Hydrochloride 69Radiosurgery 67Nivolumab 56Bevacizumab 54Drug Therapy 52Cyclophosphamide 49Magnetic Resonance Spectroscopy 46folfirinox 42Docetaxel 41Cetuximab 40Specimen Handling 37irinotecan sucrosofate 36S 1 (combination) 36Biopsy 31Radiation 29Paclitaxel 29Ipilimumab 27durvalumab 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Pancreatic Neoplasms × exemestane × Clear all
NCT06630325 2026-04-28

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

OHSU Knight Cancer Institute

Phase 2 Terminated
6 enrolled 3 charts
GastrointestinalGenitourinaryGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡